Stoke Therapeutics

General Information


We are pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression. We are developing novel antisense oligonucleotide, or ASO, medicines that target ribonucleic acid, or RNA, and modulate precursor-messenger RNA, or pre-mRNA, splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. We utilize our proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or TANGO, to design ASOs to upregulate the expression of protein by individual genes in a patient.

Employees: 49
Founded: 2014
Contact Information
Address 45 Wiggins Avenue, Bedford, MA, 01730, US
Phone Number (781) 430-8200
Web Address
View Prospectus: Stoke Therapeutics
Financial Information
Market Cap $566.3mil
Revenues $0 mil (last 12 months)
Net Income $-16.4 mil (last 12 months)
IPO Profile
Symbol STOK
Exchange NASDAQ
Shares (millions): 7.9
Price range $18.00 - $18.00
Est. $ Volume $142.0 mil
Manager / Joint Managers J.P. Morgan/ Cowen and Company/ Credit Suisse
CO-Managers Canaccord Genuity
Expected To Trade: 6/19/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change